Concepedia

One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry

Mathew W. MacCumber, Charles C. Wykoff, Hélène Karcher, Eser Adiguzel, Samriddhi Buxy Sinha, Saloni Vishwakarma, Andrew LaPrise, Franklin Igwe, Rita Freitas, Michael S. Ip,

Ophthalmology · 2023 · 18 citations · 22 references

DOI

Concepts

References

22

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Pravin U. Dugel, Adrian Koh, Yuichiro Ogura et al. · Ophthalmology · 2019 · 871 citations · Full text

HAWK and HARRIER

Pravin U. Dugel, Rishi P. Singh, Adrian Koh et al. · Ophthalmology · 2020 · 358 citations

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab

Jordi Monés, Sunil Srivastava, Glenn J. Jaffe et al. · Ophthalmology · 2020 · 338 citations · Full text

Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial

Pravin U. Dugel, Glenn J. Jaffe, Peter Sallstig et al. · Ophthalmology · 2017 · 226 citations

, , +4

Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study

Louisa M. Bulirsch, Marlene Saßmannshausen, Jennifer Nadal et al. · British Journal of Ophthalmology · 2021 · 119 citations · Full text